Premium
Halofenate, serum lipids, and exercise performance in coronary heart disease
Author(s) -
Aronow Wilbert S.,
Vangrow Jack S.,
Nelson William H.,
Pagano James,
Papageorge's Nicholas P.,
Khurshee Mohammed,
Harding Phillip R.,
Khemka Mahaveer
Publication year - 1974
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt197415167
Subject(s) - hypertriglyceridemia , medicine , angina , triglyceride , cardiology , placebo , blood lipids , cholesterol , myocardial infarction , alternative medicine , pathology
We have already reported the effect on serum lipids and exercise performance of halofenate administered for 48 weeks to 48 patients with hypertriglyceridemia in a 14 month double‐blind study. Forty‐one of these patients received halofenate for an additional 48 weeks. In 21 patients with hypertriglyceridemia, halofenate significantly lowered the mean serum triglyceride level from the control period 21 % during the first 48 weeks of therapy and 27% during the second 48 weeks of therapy. In another 20 patients with hypertriglyceridemia, halofenate significantly lowered the mean serum triglyceride level from the control plus placebo period 26% during 48 weeks of therapy. Halofenate did not significantly affect mean serum cholesterol levels. Halofenate did not significantly affect the exercise performance until angina in 24 anginal patients or the resting or exercise electrocardiograms in 41 patients, including 28 with documented coronary heart disease. At the end of this 25 month study, 6 of 23 surviving anginal patients (26%) had no angina following exercise, and 14 of 23 surviving anginal patients (61 %) had no angina or at least a 25% increase in exercise time until angina, attributed to the natural history of coronary heart disease.